(Q43660230)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11435064%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

title

A phase II trial of oral eniluracil/5-fluorouracil in patients with inoperable hepatocellular carcinoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11435064%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

main subject

phase II clinical trial

0 references

author

Josep M. Llovet

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11435064%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

Jordi Bruix

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11435064%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

Lluís Castells

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11435064%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

author name string

P Ruff

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11435064%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

N Tassopoulos

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11435064%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

I El-Hariry

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11435064%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

M Peachey

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11435064%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

publication date

1 July 2001

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11435064%20AND%20SRC:MED&resulttype=core&format=json

European Journal of Cancer

9 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11435064%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

volume

37

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11435064%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11435064%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

page(s)

1352-1358

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11435064%20AND%20SRC:MED&resulttype=core&format=json

Epidemiology of primary liver cancer

9 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900100-9

7 January 2021

Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900100-9

7 January 2021

Prognosis of hepatocellular carcinoma: the BCLC staging classification

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900100-9

7 January 2021

Treatment of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900100-9

7 January 2021

Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900100-9

7 January 2021

A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900100-9

7 January 2021

Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900100-9

7 January 2021

Review article: Overview of medical treatments in unresectable hepatocellular carcinoma--an impossible meta-analysis?

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900100-9

7 January 2021

Treatment of hepatocellular carcinoma: a systematic review of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900100-9

7 January 2021

Treatment of hepatocellular carcinoma with tamoxifen: A double-blind placebo-controlled trial in 120 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900100-9

7 January 2021

Clinical trials in primary hepatocellular carcinoma: current status and future directions

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900100-9

7 January 2021

5-Ethynyluracil (776C85): inactivation of dihydropyrimidine dehydrogenase in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900100-9

7 January 2021

Pharmacokinetic, oral bioavailability, and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900100-9

7 January 2021

Phase I and pharmacologic study of oral fluorouracil on a chronic daily schedule in combination with the dihydropyrimidine dehydrogenase inactivator eniluracil

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900100-9

7 January 2021

Phase II study of 5-fluorouracil (5-FU) and high dose folinic acid (HDFA) in hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900100-9

7 January 2021

5-Fluorouracil and high-dose calcium leucovorin for hepatocellular carcinoma: a phase II trial

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900100-9

7 January 2021

5-Fluorouracil and d,l-leucovorin calcium are active to treat unresectable hepatocellular carcinoma patients: preliminary results of a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900100-9

7 January 2021

Low-dose oral fluorouracil with eniluracil as first-line chemotherapy against advanced breast cancer: a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900100-9

7 January 2021

Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900100-9

7 January 2021

The determinatio of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900100-9

7 January 2021

Population characteristics of hepatic dihydropyrimidine dehydrogenase activity, a key metabolic enzyme in 5-fluorouracil chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900100-9

7 January 2021

Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900100-9

7 January 2021

Overexpression of the MDR1 gene and P-glycoprotein in human hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900100-9

7 January 2021

Implications of the p53 tumor-suppressor gene in clinical oncology.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900100-9

7 January 2021

Thymidylate synthase and drug resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900100-9

7 January 2021

10.1016/S0959-8049(01)00100-9

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11435064%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

1 reference